Key facts
- Immuto Scientific’s last known valuation is $6.3M (Oct 2021).
- It has raised $10.4M; the latest was Seed Round ($8.0M) in Sep 2025.
- Notable investors include gBETA, Great Oaks Venture Capital, Wisconsin Economic Development, WARF Ventures, Golden Angels Investors — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Immuto Scientific
- ·The full record, as it builds
Funding rounds
No funding rounds for Immuto Scientific are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Immuto Scientific
Developer of a protein footprinting technology designed to analyse proteins in the drug development process. The company's technology automates complex protein analysis as part of the drug discovery process for protein therapeutics which is more fast than the industry gold standard technique for protein structure analysis, enabling drug developers to determine the protein structure quickly.
- Sector
- Healthcare
- HQ
- Madison, WI, United States
- Founded
- 2017
- Employees
- 18
- Website
- immutoscientific.com/
- Ownership
- Privately Held (backing)
Immuto Scientific doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immuto Scientific shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immuto Scientific in its N-PORT filings yet. We sweep new filings monthly.